MX9306528A - Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido. - Google Patents

Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido.

Info

Publication number
MX9306528A
MX9306528A MX9306528A MX9306528A MX9306528A MX 9306528 A MX9306528 A MX 9306528A MX 9306528 A MX9306528 A MX 9306528A MX 9306528 A MX9306528 A MX 9306528A MX 9306528 A MX9306528 A MX 9306528A
Authority
MX
Mexico
Prior art keywords
hetero
cycloalkyl
hydroxy
annular
cyclic compounds
Prior art date
Application number
MX9306528A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9306528A publication Critical patent/MX9306528A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos de la fórmula I, y sus sales y profármacos farmacéuticamente aceptables; en donde X1, Ar, X, Y1, R1, R2, R3, R5, y n son como se define más adelante, que son inhibidores de la producción de leucotrienos y/o bloqueadores de receptores de leucotrieno; métodos para preparar dichos compuestos e intermediarios útiles en su preparación; sus composiciones farmacéuticas, y métodos de tratamiento con ellas. Los compuestos de la fórmula anterior son útiles en la prevención o tratamiento de asma, artritis, psoriasis, úlceras, infartos al miocardio y enfermedades relacionadas, en mamíferos.
MX9306528A 1992-10-21 1993-10-20 Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido. MX9306528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96433792A 1992-10-21 1992-10-21

Publications (1)

Publication Number Publication Date
MX9306528A true MX9306528A (es) 1994-06-30

Family

ID=25508435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306528A MX9306528A (es) 1992-10-21 1993-10-20 Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido.

Country Status (23)

Country Link
US (1) US5641789A (es)
EP (1) EP0665842A1 (es)
JP (1) JPH07508534A (es)
KR (1) KR950704309A (es)
CN (1) CN1090282A (es)
AP (1) AP9300578A0 (es)
AU (1) AU5536794A (es)
BR (1) BR9307277A (es)
CA (1) CA2146261A1 (es)
CZ (1) CZ100095A3 (es)
FI (1) FI934625A (es)
HR (1) HRP931297A2 (es)
HU (1) HUT68323A (es)
IL (1) IL107294A0 (es)
MA (1) MA23009A1 (es)
MX (1) MX9306528A (es)
NO (1) NO303224B1 (es)
PL (1) PL308474A1 (es)
RU (1) RU95109929A (es)
SI (1) SI9300554A (es)
TW (1) TW265335B (es)
WO (1) WO1994008996A1 (es)
ZA (1) ZA937782B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539128A (en) * 1994-11-30 1996-07-23 Pfizer Inc. Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
AU713701B2 (en) * 1996-09-16 1999-12-09 Pfizer Inc. Processes and intermediates for preparing substituted chromanol derivatives
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
GB9800039D0 (en) * 1998-01-02 1998-03-04 Univ Cardiff Benzyl and benzylidene tetralins and derivatives
RU2182004C1 (ru) * 2001-02-22 2002-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственный препарат для парентерального применения
CN100516059C (zh) * 2001-04-10 2009-07-22 宝生物工程株式会社 治疗剂
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
AU2003301305A1 (en) * 2002-10-17 2004-05-04 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
CA2539276A1 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US20060210514A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin protection and moisturizing compositions and method of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059609A (en) * 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
FI934625A0 (fi) 1993-10-20
US5641789A (en) 1997-06-24
CN1090282A (zh) 1994-08-03
HUT68323A (en) 1995-06-28
NO951506D0 (no) 1995-04-20
FI934625A (fi) 1994-04-22
AP9300578A0 (en) 1995-04-07
KR950704309A (ko) 1995-11-17
AU5536794A (en) 1994-05-09
ZA937782B (en) 1995-04-20
CZ100095A3 (en) 1995-11-15
SI9300554A (en) 1995-04-30
HU9302969D0 (en) 1993-12-28
WO1994008996A1 (en) 1994-04-28
NO951506L (no) 1995-04-20
NO303224B1 (no) 1998-06-15
EP0665842A1 (en) 1995-08-09
PL308474A1 (en) 1995-08-07
JPH07508534A (ja) 1995-09-21
IL107294A0 (en) 1994-01-25
BR9307277A (pt) 1999-05-11
CA2146261A1 (en) 1994-04-28
MA23009A1 (fr) 1994-07-01
HRP931297A2 (en) 1996-08-31
RU95109929A (ru) 1997-03-20
TW265335B (es) 1995-12-11

Similar Documents

Publication Publication Date Title
MX9306528A (es) Derivados de sulfonamida de compuestos anulares de cicloalquilo-heterociclico substituidos con hidroxi, de benceno fundido.
BR0206435A (pt) Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos
UY26143A1 (es) Derivados heterocíclicos útiles como agentes anticancerosos
ES2134859T3 (es) Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.
ES542320A0 (es) Un procedimiento para la preparacion de derivados de la 2 pirimidinil 1 piperazina
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
DK0647219T3 (da) Derivater i vitamin D-serien modificeret i 20-positionen, fremgangsmåde til fremstilling af sådanne derivater, mellemprodukter itl brug ved fremgangsmåde, farmaceutiske præparater indeholdende derivaterne samt deres anvendelse ved fremstilling af lægemidler
ES2117133T3 (es) Derivados peptidilicos del acido 4-amino-2,2-difluoro-3-oxo-1,6-hexanodioico como agentes antiinflamatorios.
ECSP034917A (es) Nuevos derivados de acido sulfonico
MX9301240A (es) Derivados heterociclicos de cetona, condensados, metodo para su produccion y composicion farmaceutica que los contiene.
NO168582C (no) Analogifremgangsmaate for fremstilling av nye, terapeutiskvirksomme dihydrobenzofuran- og chroman-carboxamidderivater
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
HUP0000321A2 (hu) NOS inhibitor hatású aromás aminszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
NO950683L (no) Nye 2-substituterte indan-2-merkaptoacetylamidtrisykliske derivater som er anvendbare som inhibitorer av enkefalinase
AR004726A1 (es) Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FI92199B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
UY26079A1 (es) Nuevos derivados de morfolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9300638A (es) Derivados del acido aminobenzoico.
AR247197A1 (es) Procedimiento para preparacion de nuevos compuestos broncoespasmoliticos
AR032373A2 (es) Intermediarios para preparar 3-(1-piperazinil)-1,2-benzoisotiazol.
ES2038218T3 (es) Un procedimiento para preparar nuevos derivados de 2-alquilsulfinil-4(3h)-quinazolinona.
UY24832A1 (es) Nuevos compuestos derivados del benzoperhidroisoindol, útiles como inhibidores de la farnesil transferasa, procedimiento para prepararlos, los intermediarios de sintesis y su preparación, las composiciones farmacéuticas que contienen dichos derivados